Jump to content

MK7684A-003 Study


Recommended Posts

Visit https://merckoncologyclinicaltrials.com/en-us/patient/trial/NCT04738487 or call 888-577-8839 for more information

MK7684A-003 -  Coformulation of Pembrolizumab/Vibostolimab versus Pembrolizumab monotherapy for programmed cell death 1 ligand 1 (PD-L1) positive metastatic non-small cell lung cancer (NSCLC) (NCT04738487)

You can be able to join this study if you have NSCLC and have not been treated for cancer cells that may have spread through your body.

The drug you get will depend on which group you are placed in. You have an equal chance (50/50) of being placed in each group.

This trial has 2 groups:

Group 1 will get MK-7684A

Group 2 will get pembro

You, your trial doctor, and the trial staff won’t know what drug you are getting. In case of a health emergency, they can find out.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.